Emerging JWA-targeted Pt(IV) prodrugs conjugated with CX-4945 to overcome chemo-immune-resistance.
Sign Up to like & getrecommendations! Published in 2019 at "Biochemical and biophysical research communications"
DOI: 10.1016/j.bbrc.2019.10.184
Abstract: Two Pt(IV) prodrugs, Cx-platin-Cl and Cx-DN604-Cl, derived from the conjugation of cisplatin or DN604 with a CK2 inhibitor CX-4945, were constructed to suppress DNA damage repair-related elements. During in vitro biological studies, the Pt(IV) prodrugs had… read more here.
Keywords: platin dn604; immune resistance; chemo immune; resistance ... See more keywords
JWA suppresses proliferation in trastuzumab-resistant breast cancer by downregulating CDK12
Sign Up to like & getrecommendations! Published in 2021 at "Cell Death Discovery"
DOI: 10.1038/s41420-021-00693-9
Abstract: Breast cancer is the most common cancer worldwide. JWA is a microtubule-associated protein that has been identified as a tumor suppressor, and its downregulation in tumors is an independent adverse prognostic factor. The objective of… read more here.
Keywords: breast; trastuzumab resistant; resistant breast; jwa ... See more keywords